Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. is poised for growth, with Baqsimi sales projected to increase approximately 20% quarter-over-quarter in Q3 2025, bolstered by collaborations and seasonal demand. The company is expected to achieve flat year-over-year top-line results in 2025 followed by a return to double-digit growth in 2026, indicating a strong recovery trajectory. Furthermore, expectations of high-single digit unit growth for 2025, combined with the favorable seasonal performance of products like Primatene Mist, contribute to a positive outlook for Amphastar's financial future.

Bears say

Amphastar Pharmaceuticals Inc. is experiencing significant revenue pressures, particularly with iron sucrose and glucagon products, as increased competition and supply issues lead to a downward revision of expected sales from previously optimistic projections. The shift in market dynamics has resulted in a forecast that annual glucagon sales may drop below $70 million starting in 2026, indicating an unfavorable outlook driven by the entry of new competitors. Furthermore, expectations for a return to double-digit top-line growth have been tempered to a forecast of high-single digit to low-double digit growth, reflecting concerns over the company's current pipeline and market conditions.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.